| 02/14/07 |
Imagenetix Reports Third Quarter Fiscal Results
Launch of retail branding program on target and expect substantial revenue increase in fourth fiscal quarter. |
| 12/11/06 |
Imagenetix Receives FDA Clearance to Begin Pre-IND Safety Studies on Anti-Inflammatory Compound
1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions |
| 08/21/06 |
Imagenetix Launches Retail Branding Program; Former Pharmavite Executives To Spearhead Campaign
The first products to be branded under the program will be the company's Celadrin®-based joint health formulas. |
| 06/26/06 |
Imagenetix Appoints Former FDA, NIH Staffer to Guide IND Submission for Anti-Inflammatory Compound
Imagenetix has engaged the services of Michael Hamrell, Ph.D., president of MORIAH Consultants, a regulatory affairs and clinical research consulting firm near Los Angeles |
| 06/01/06 |
Imagenetix Announces Positive Safety Studies on Anti-Inflammatory Compound, 1-TDC
1-tetradecanol complex (1-TDC) has achieved expected results in important baseline acute toxicity studies... |
| 05/08/06 |
Imagenetix Announces 1-Tetradecanol Complex Acts to Inhibit Bacteria and Enzymes Associated with Oral Disease, Sepsis and Inflammation
1-TDC significantly inhibited the growth of Actinomyces
viscosus, a microbe that has been shown to play a major role in oral
microbial ecosystems... |
| 04/17/06 |
Imagenetix Commences China Sales of New Patented Weight Loss Product
Imagenetix announced it has introduced its weight loss compound,
Lepitrim(TM), to the Peoples Republic of China. |
| 03/20/06 |
Imagenetix Commissions New Study to Evaluate Celadrin(R) Capsules for Patients with Knee Osteoarthritis
The primary purpose of this study is to confirm the positive
clinical results, published in 2002 in the internationally acclaimed
peer-reviewed Journal of Rheumatology... |
| 11/30/05 |
Imagenetix Announces Release of Celadrin/Glucosamine Combination Product
The new Glucosamine/Celadrin® combination is expected
to produce enhanced action of its two components... |
| 11/22/05 |
Imagenetix Second Quarter Revenue up 95 Percent
Non-Cash Charge of $5.3 Million Related to Warrants and
Options Results in Loss |
| 11/16/05 |
Imagenetix Licenses Patent Related to Body Fat Control
Commercialization of Fat Reduction Product to Commence
Immediately |
| 09/27/05 |
Jeffrey McGonegal Appointed to Imagenetix Board of Directors and Appointed Chairman of the Audit Committee and Its Financial Expert
Mr. McGonegal has unique in-depth expertise in merger and acquisition matters,
in analyzing financial alternatives for growth oriented companies |
| 09/26/05 |
Bob Burg Appointed to Imagenetix Board of Directors
Owner of The Burg Group, Mr. Burg's 25 years of business
experience have focused on sales and marketing campaigns, channel
distribution, and product sourcing. |
| 08/16/05 |
Imagenetix Reports Record Quarter
Sales Hit All Time
High - Up 142%. Before-Tax Income Soars 174%. Company Reports Ten Consecutive
Quarters of Operating Profits |
| 07/20/05 |
Imagenetix
Reports Record Year
Sales Jump 66% -- Net Income Increases 62%, and Company Reports
Nine Consecutive Quarters of Profits |
| 05/03/05 |
Jason
Theodosakis and Lorna Vanderhaeghe Join Imagenetix's Scientific
and Medical Advisory Board
Bill Spencer, CEO of Imagenetix, said, "It gives me great pleasure
to welcome Dr. Jason Theodosakis and Lorna Vanderhaeghe, two highly
regarded authors and internationally acclaimed medical and health
professionals to the Imagenetix Scientific and Medical Advisory Board." |
| 04/21/05 |
Joining the Imagenetix Scientific and Medical Advisory Board are
Robert B. Zurier, M.D., and William J. Kraemer, Ph.D
Bill Spencer, CEO of Imagenetix said, “We are very
pleased to welcome Robert Zurier, M.D., who is a highly respected
researcher and an expert in rheumatoid arthritis... |
| 04/13/05 |
Dr. Reddy's Launches Celadrin® as A Pharmaceutical Product in India
Celadrin has been approved for use as a pharmaceutical
product in India to help reduce pain and inflammation in patients
with joint conditions. |
| 04/07/05 |
Imagenetix
Announces Formation of Scientific and Medical Advisory Board
Scientific and Medical Advisory Board that will lend guidance
to the company's research and provide counsel related to product development |
| 02/22/05 |
Imagenetix
Reports Third Quarter Results
For the third fiscal quarter ended December 31, 2004, the
Company reported revenue of $2,739,743, a 157% increase |
| 11/23/04 |
Sales
and Earnings Increase at Imagenetix as Company Reports Seventh
Consecutive Quarter of Profitability
For the second fiscal quarter ended September 30, 2004,
the company reported revenue of $1,034,146.00 |
| 08/23/04 |
Earnings
Increase 280% at Imagenetix
For the first fiscal quarter ended June 30, 2004, the company
reported revenue of $1,186,163 |
| 07/19/04 |
RFourth
Quarter Sales Increase 60% and Earnings Increase 460% as Imagenetix
Reports Record Fourth Quarter and Year End Results
For the fourth fiscal quarter ended March 31, 2004, the company
reported revenue of $1,645,199, a 60% increase |
| 04/01/04 |
Researchers
Discover Arthritis Topical Cream Significantly Reduces Symptoms
Imagenetix Announced the Publication of Its Clinical Study in The Journal
of Rheumatology |
| 02/17/04 |
Imagenetix
Reports 31% Increase in Quarterly Sales and Fourth Consecutive
Quarter of Profitability
For the third fiscal quarter ended December 31, 2003, the company reported
revenue of $1,066,399, an increase of 31% |
| 11/13/03 |
Imagenetix
Congratulates Newport Bioceuticals On Successful Television Infomercial
Test-Airing of Zylogen Real Pain Relief
The infomercial features Zylogen(TM) Real Pain Relief which provides penetrating
pain relief for minor aches and pains of muscles and joints associated
with arthritis, simple backache, strains, bruises, and sprains. |
| 07/14/03 |
Imagenetix Reports
Fourth Quarter and Year End Results
www.imagenetix.net, an innovator of scientifically tested, natural based,
proprietary bioceutical products developed to enhance human and animal
health on a global basis, today announced fiscal results for the fourth
quarter and year ended March 31, 2003. |
| 05/30/03 |
Cetylated Fatty
Acid Cream Improves Quality of Life, Functional Performance and
Range of Motion in Clinical Study
A topical cream composed of cetylated fatty acids (CFA) can improve quality
of life and mobility in patients with osteoarthritis |
| 04/28/03 |
Imagenetix
Expands Marketing Efforts
Initial test marketing of select private labeled products is scheduled
to begin over the radio and through a television infomercial during the
next 45 days. |
| 04/14/03 |
Imagenetix Presents
Data From Clinical study on Cetylated Fatty Acids Absorption
and Metabolism at Experimental Biology 2003 Conference
San Diego based Imagenetix, Inc. www.imagenetix.net (OTCBB: IAGX) announces
promising research on the bioavailability of a proprietary Imagenetix compound
was detailed in a poster presentation at the Experimental Biology 2003
Conference in San Diego on Saturday, April 12. |
| 04/02/03 |
Imagenetix Files
Patent on Genepril™
Imagenetix is seeking claims for the prevention and treatment of various
types of arthritis and other inflammatory joint diseases as well as psoriasis,
lupus, and cardiovascular conditions. |
